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Background
Breast cancer is the main cancer type affecting women in
the Kingdom of Saudi Arabia. The relatively young age of
onset in this population could be explained by the inter-
play between common genetic susceptibility background
substantiated by increased consanguinity and epigenetic
aberrations caused by the shift in life style experienced in
this region [1]. Genomic screening of breast cancer
patients is beneficial in identifying underlying variants that
could explain increased susceptibility to breast cancer.
However, it is important to understand the epigenetic
aberrations associated with breast cancer in order to shed
light on its etiology and identify possible treatments. To
this end, we have performed MBD-Seq on a cohort of
breast cancer samples that led to the identification of
tumor-specific methylation of the MTNR1B promoter in a
significant number of breast cancer cases from Saudi
Arabia.
Materials and methods
Methyl binding domain-sequencing (MBD-Seq) was
applied on DNA extracted from surgically-resected breast
tumors using the MethylMiner™ kit from Invitrogen fol-
lowed by fragment identification using next generation
sequencing on the SOLiD platform (Applied Biosystems).
Determination of methylation frequency and correlation
with clinicopathological parameters was performed using
the MethyLight assay on DNA extracted from FFPE
tissues. Fisher’s exact test and univariant Kaplan-Meier
survival analysis were applied where p<0.05 considered
statistically significant.
Results
MTNR1B methylation frequency in breast cancer is 35%
(n=157). MTNR1B methylation was largely limited to the
IDC, ILC and DCIS subtypes. Furthermore, MTNR1B
methylation is significantly associated with histological
grade I of breast cancer (p=0.019, n=128). The associa-
tion of MTNR1B methylation and disease-free or specific
survival is investigated.
Conclusions
Finding significant levels of methylation of a key circa-
dian clock gene as the MTNR1B in a tumor-specific
fashion may provide an intriguing evidence to the role
of environmental factors (day-night cycles) and breast
cancer development.
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